Search Results

Active, currently enrolling    Who can join   

A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)

Keywords: Loncastuximab Tesirine; Refractory Diffuse Large B-Cell Lymphoma; Relapsed…
Study Type: INTERVENTIONAL   |  Region: Northwest

---

Active, currently enrolling    Who can join   

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase III (S1501)

Keywords: Oncology (Adult); S1501; Breast Neoplasms; Neoplasms; Cardiotoxicity; Neoplasms…
Study Type: INTERVENTIONAL   |  Region: Northwest

---

Active, not yet recruiting    Who can join   

A Phase 2, Open-Label, Randomized, Global Study of Two Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Keywords: Oncology (Adult);
Study Type: INTERVENTIONAL   |  Region: Hawaii

---

Active, currently enrolling    Who can join   

A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)

Keywords: Oncology (Adult);
Study Type: INTERVENTIONAL   |  Region: Hawaii

---

Enrollment complete    Who can join   

AstraZeneca ADAURA D5164C00001: A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Keywords: Oncology (Adult);
Study Type: INTERVENTIONAL   |  Region: Hawaii

---

Active, enrolling only by invitation    Who can join   

A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Keywords: Oncology (Adult);
Study Type: INTERVENTIONAL   |  Region: Hawaii

---

Active, currently enrolling    Who can join   

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence

Keywords: Oncology (Adult);
Study Type: INTERVENTIONAL   |  Region: Hawaii

---

Enrollment complete    Who can join   

BO41843: A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

Keywords: Oncology (Adult);
Study Type: INTERVENTIONAL   |  Region: Hawaii

---

Active, currently enrolling    Who can join   

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Keywords: Oncology (Adult);Urology;
Study Type: INTERVENTIONAL   |  Region: California - Northern

---

Active, currently enrolling    Who can join   

EXActDNA-003 / NSABP B-64: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease

Keywords: Oncology (Adult);Breast Cancer; ctDNA; Neoplasms by Site; Neoplasms; Breast…
Study Type: OBSERVATIONAL   |  Region: California - Northern

---